Not exact matches
Looking to target a key pathway in order to interfere with the processes that lead to
tumor spread, a research team led by Irwin H. Gelman, Ph.D., of Roswell Park Cancer Institute (RPCI) has
identified a new suppressor of cancer
metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid
tumors.
«How melanoma
tumors form: Team
identifies drugs that halt skin cancer
metastasis in lab tests.»
Cheng and colleagues did experiments using human cells and
identified hnRNPM's role in controlling the processes linked to
tumor metastasis.
By
identifying the cause of this
metastasis — which often happens quickly in lung cancer and results in a bleak survival rate — Salk scientists are able to explain why some
tumors are more prone to spreading than others.
They showed that the iKnife could distinguish normal and
tumor tissues from different organs, such as breast, liver, and brain, and could even
identify the origin of a
tumor that was a
metastasis, a secondary growth seeded by a primary
tumor elsewhere in the body.
Pandolfi and colleagues sought to
identify an additional
tumor suppressing gene or pathway that may work in concert with PTEN to drive
metastasis.
Despite this clinical importance, the exact pathologic process of
tumor metastasis is as yet poorly understood, and deciphering the exact molecular mechanism of this process is of paramount importance to
identify specific therapeutic targets for this devastating disease.
So although genetic sequencing has
identified hundreds of genetic alterations linked to
tumors, it's still an enormous challenge to figure out which ones are actually responsible for the growth and
metastasis of cancer.
Houston Methodist researchers led by Dario Marchetti, PhD, have developed a blood test that can
identify circulating
tumor cells to predict breast cancer patients at risk for developing brain
metastasis.
Researchers at the Université libre de Bruxelles, ULB define for the first time the
tumor transition states occurring during cancer progression and
identify the
tumor cell populations responsible for
metastasis.
The idea was to
identify genes that were
metastasis determinants by correlating gene expression with some kind of invasion assay that measured
tumor progression.
The application of subclonal reconstruction methods is providing key insights into
tumor evolution,
identifying subclonal driver mutations, patterns of parallel evolution and differences in mutational signatures between cellular populations, and characterizing the mechanisms of therapy resistance, spread, and
metastasis.
Haihui Lu, Ph.D., a CRI fellow at the Whitehead Institute for Biomedical Research, has
identified a surface marker that distinguishes a population of breast cancer cells that are more prone to
metastasis and demonstrate higher levels of «stemness,» the ability to seed other
tumors.
Roswell Park Cancer Institute researchers have
identified a gene that influences
metastasis in prostate cancer, and may help clinicians to
identify aggressive prostate
tumors before they progress and spread to other organs.
There are three grades: Grade I
tumors are easily
identified and rarely metastasize; Grade II
tumors have intermediate differentiation and extend deeper into the underlying tissues and about 20 percent will spread or metastasize; Grade III
tumors are poorly differentiated and behave aggressively with an 80 percent or higher chance of
metastasis.
It may also help to
identify concurrent problems such as bladder stones, changes in appearance of the liver or
metastasis from an adrenal
tumor.